Home › Companies › SUTRO BIOPHARMA INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 5 items on SUTRO BIOPHARMA INC.’s Form 8-K, filed June 10, 2024: 5 passed (calculated).
Significant dissent: 1 director (34.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 1.3%, as of September 30, 2026)
Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joseph M. Lobacki | 49,578,870 | -- | -- | 1,393,863 | 13,906,799 | 97% | Passed (calculated) | — |
| Elect Director: Daniel H. Petree | 33,386,033 | -- | -- | 17,586,700 | 13,906,799 | 65% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 64,598,771 | 118,896 | 161,865 | -- | -- | 99.8% | Passed (calculated) | — |
| 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers | 50,214,198 | 171,189 | 587,346 | -- | 13,906,799 | 99.7% | Passed (calculated) | — |
| 4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and (ii) make certain non-substantive clari | 50,224,587 | 618,712 | 129,434 | -- | 13,906,799 | 99% | Passed (calculated) | — |
Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
144 asset managers disclosed a vote on at least one SUTRO BIOPHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Daniel H. Petree
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Daniel H. Petree”): 33,386,033 for, 17,586,700 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 7,895,863 for, 2,282,950 withheld, 152,276 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,338,900 | 0 | 0 | 500 | For |
| Dimensional | 0 | 0 | 0 | 792,430 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 505,154 | Withhold |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 108,716 | 0 | 0 | 75,300 | Mixed |
| Nationwide | 941 | 0 | 0 | 164,047 | Withhold |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 149,005 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 145,200 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 74,398 | Withhold |
| ETF Series Solutions | 0 | 0 | 71,577 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 69,389 | Withhold |
| Lincoln Financial | 1,702 | 0 | 0 | 52,178 | Withhold |
| GuideStone | 0 | 0 | 0 | 48,744 | Withhold |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 30,740 | Withhold |
| John Hancock | 0 | 0 | 27,512 | 0 | Abstain |
| Northern Trust | 0 | 0 | 0 | 27,332 | Withhold |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 0 | 0 | 0 | 22,601 | Withhold |
| Voya | 0 | 0 | 0 | 22,229 | Withhold |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Joseph M. Lobacki
SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Joseph M. Lobacki”): 49,578,870 for, 1,393,863 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 9,427,765 for, 883,935 withheld, 19,389 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 792,430 | Withhold |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 108,716 | 0 | 0 | 75,300 | Mixed |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,802 | 0 | 0 | 2,078 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,740 | 0 | 0 | 0 | For |
| John Hancock | 25,747 | 0 | 1,765 | 0 | Mixed |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 22,601 | 0 | 0 | 0 | For |
| Voya | 22,229 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall limit on the number of shares that may be issued under our ESPP throughout its ten-year term, and (ii) make certain non-substantive clarifying revisions.
SUTRO BIOPHARMA INC.’s own tally for this item (“4. Approval of the amendment of the Company's 2018 Employee Stock Purchase Plan (the " ESPP ") to (i) increase the overall limit on the number of shares that may be issued under the ESPP throughout its ten-year term, and”): 50,224,587 for, 618,712 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,047 | 941 | 0 | 0 | For |
| Charles Schwab | 0 | 160,876 | 0 | 0 | Against |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 30,928 | 0 | 0 | Against |
| AIG/SunAmerica | 30,740 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 22,601 | 0 | 0 | 0 | For |
Fund voting reports, all 52 managers: 10,097,161 for, 233,928 against, 120,000 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,892,497 | Withhold |
| Eversept Partners, LP | 1,488,828 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 0 | 23,761 | 0 | 0 | Against |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 0 | 1,372 | 0 | 0 | Against |
Institutional-manager reports, all 4 managers: 1,488,828 for, 25,133 against, 1,892,497 withheld.
Combines 6 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Prior year: 80.7% for (June 8, 2023 meeting) ▲ 19.0 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
SUTRO BIOPHARMA INC.’s own tally for this item (“3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers”): 50,214,198 for, 171,189 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,740 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 22,601 | 0 | 0 | 0 | For |
Fund voting reports, all 52 managers: 10,309,827 for, 8,043 against, 120,000 withheld, 13,219 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,608,682 | 0 | 0 | 0 | For |
| Point72 | 5,847,686 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 4,121,208 | 0 | 0 | 0 | For |
| BlackRock | 2,305,607 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,241,629 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,892,497 | Withhold |
| BAILLIE GIFFORD & CO LTD | 1,793,154 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 1,488,828 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,305,468 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,271,235 | 0 | 0 | 0 | For |
| State Street | 1,109,150 | 0 | 0 | 0 | For |
| Two Sigma | 1,071,064 | 0 | 0 | 0 | For |
| Aquilo Capital Management, LLC | 987,396 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 587,776 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 530,478 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 481,509 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 0 | 440,369 | 0 | Abstain |
| Nuveen | 438,538 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 427,262 | 0 | 0 | 0 | For |
| Renaissance | 370,407 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 334,079 | 0 | 0 | 0 | For |
| DE Shaw | 296,983 | 0 | 0 | 0 | For |
| UBS | 275,057 | 0 | 0 | 0 | For |
| Northern Trust | 271,556 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 269,486 | 0 | 0 | 0 | For |
Institutional-manager reports, all 110 managers: 38,148,356 for, 102,693 against, 1,892,497 withheld, 440,369 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Prior year: 99.9% for (June 8, 2023 meeting) ▼ 0.1 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
SUTRO BIOPHARMA INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 64,598,771 for, 118,896 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 52 asset managers below reported 10,317,705 for, 165 against, 120,000 withheld, 13,219 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,983,134 | 0 | 0 | 0 | For |
| BlackRock | 2,633,809 | 0 | 0 | 0 | For |
| Fidelity | 1,339,400 | 0 | 0 | 0 | For |
| Dimensional | 792,430 | 0 | 0 | 0 | For |
| Goldman Sachs | 505,154 | 0 | 0 | 0 | For |
| TIAA | 434,955 | 0 | 0 | 0 | For |
| Equitable | 184,016 | 0 | 0 | 0 | For |
| Nationwide | 164,988 | 0 | 0 | 0 | For |
| Charles Schwab | 160,876 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 149,005 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 145,200 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 120,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 113,702 | 0 | 0 | 0 | For |
| American Century | 74,398 | 0 | 0 | 0 | For |
| ETF Series Solutions | 71,577 | 0 | 0 | 0 | For |
| Aberdeen | 69,389 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,880 | 0 | 0 | 0 | For |
| GuideStone | 48,744 | 0 | 0 | 0 | For |
| Russell Investments | 30,928 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 30,740 | 0 | 0 | 0 | For |
| John Hancock | 27,512 | 0 | 0 | 0 | For |
| Northern Trust | 27,332 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 24,111 | 0 | 0 | 0 | For |
| Pacific Life | 23,421 | 0 | 0 | 0 | For |
| State Street | 22,601 | 0 | 0 | 0 | For |
Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 81,794,334 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.65% |
| 2 | BlackRock | 3.22% |
| 3 | Fidelity | 1.64% |
| 4 | Dimensional | 0.97% |
| 5 | Goldman Sachs | 0.62% |
| 6 | TIAA | 0.53% |
| 7 | Equitable | 0.22% |
| 8 | Nationwide | 0.20% |
| 9 | Charles Schwab | 0.20% |
| 10 | Columbia Threadneedle | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.30% |
| 2 | Point72 | 7.15% |
| 3 | MPM BioImpact LLC | 5.04% |
| 4 | BlackRock | 2.82% |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.74% |
| 6 | Kynam Capital Management, LP | 2.31% |
| 7 | BAILLIE GIFFORD & CO LTD | 2.19% |
| 8 | Eversept Partners, LP | 1.82% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.60% |
| 10 | Samsara BioCapital, LLC | 1.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| S | 5,778,188 | 7.06% | Schedule 13G, filed February 13, 2024 |
| Suvretta Capital Management, LLC | 5,778,188 | 7.06% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Adage Capital Partners GP, LLC | 4,467,796 | 5.46% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Vanguard Group | 3,682,986 | 4.50% | Form 13F, quarter ended March 31, 2024 |
| Integrated Core Strategies (US) LLC | 3,451,825 | 4.22% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| BVF Inc. | 3,347,946 | 4.09% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Rubric Capital Management LP | 3,344,810 | 4.09% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| William J. Newell | 1,726,068 | 2.11% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| BlackRock | 1,687,880 | 2.06% | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 1,308,884 | 1.60% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 81,794,334 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At SUTRO BIOPHARMA INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 144 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 895 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99.7% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUTRO BIOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “SUTRO BIOPHARMA (STRO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/sutro-biopharma-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.